Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
Author(s):
McInnes, I.B.; Mease, P.J.; Kirkham, B.; Kavanaugh, A.; Ritchlin, C.T.; Rahman, P.; Heijde, D. van der; Landewe, R.B.M.; Conaghan, P.G.; Richards, H.; Ligozio, G.; Pricop, L.; Mpofu, S.
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-12-31
Language
English
Is part of
Arthritis and Rheumatology (2014), Vol. 66, no. 12, p. 3529-3529
